These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23083033)

  • 1. Biomarkers for systemic lupus erythematosus.
    Herbst R; Liu Z; Jallal B; Yao Y
    Int J Rheum Dis; 2012 Oct; 15(5):433-44. PubMed ID: 23083033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevation of human tumor necrosis factor-like weak inducer of apoptosis in peripheral blood mononuclear cells is correlated with disease activity and lupus nephritis in patients with systemic lupus erythematosus.
    Liu ZC; Zhou QL; Li XZ; Yang JH; Ao X; Veeraragoo P; Zuo XX
    Cytokine; 2011 Mar; 53(3):295-300. PubMed ID: 21163672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of biomarkers in the assessment of lupus.
    Merrill JT; Buyon JP
    Best Pract Res Clin Rheumatol; 2005 Oct; 19(5):709-26. PubMed ID: 16150399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus.
    Yao Y; Richman L; Higgs BW; Morehouse CA; de los Reyes M; Brohawn P; Zhang J; White B; Coyle AJ; Kiener PA; Jallal B
    Arthritis Rheum; 2009 Jun; 60(6):1785-96. PubMed ID: 19479852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers for systemic lupus erythematosus.
    Ahearn JM; Liu CC; Kao AH; Manzi S
    Transl Res; 2012 Apr; 159(4):326-42. PubMed ID: 22424435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study.
    Bauer JW; Petri M; Batliwalla FM; Koeuth T; Wilson J; Slattery C; Panoskaltsis-Mortari A; Gregersen PK; Behrens TW; Baechler EC
    Arthritis Rheum; 2009 Oct; 60(10):3098-107. PubMed ID: 19790071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum TWEAK as a biomarker for disease activity of systemic lupus erythematosus.
    Choe JY; Kim SK
    Inflamm Res; 2016 Jun; 65(6):479-88. PubMed ID: 26921306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus.
    Tew GW; Rabbee N; Wolslegel K; Hsieh HJ; Monroe JG; Behrens TW; Brunetta PG; Keir ME
    Lupus; 2010 Feb; 19(2):146-57. PubMed ID: 19946034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Belimumab: review of use in systemic lupus erythematosus.
    Boyce EG; Fusco BE
    Clin Ther; 2012 May; 34(5):1006-22. PubMed ID: 22464040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus.
    Biesen R; Demir C; Barkhudarova F; Grün JR; Steinbrich-Zöllner M; Backhaus M; Häupl T; Rudwaleit M; Riemekasten G; Radbruch A; Hiepe F; Burmester GR; Grützkau A
    Arthritis Rheum; 2008 Apr; 58(4):1136-45. PubMed ID: 18383365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.
    Merrill JT; Wallace DJ; Petri M; Kirou KA; Yao Y; White WI; Robbie G; Levin R; Berney SM; Chindalore V; Olsen N; Richman L; Le C; Jallal B; White B;
    Ann Rheum Dis; 2011 Nov; 70(11):1905-13. PubMed ID: 21798883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial.
    Tseng CE; Buyon JP; Kim M; Belmont HM; Mackay M; Diamond B; Marder G; Rosenthal P; Haines K; Ilie V; Abramson SB
    Arthritis Rheum; 2006 Nov; 54(11):3623-32. PubMed ID: 17075807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic lupus erythematosus biomarkers: the challenging quest.
    Arriens C; Wren JD; Munroe ME; Mohan C
    Rheumatology (Oxford); 2017 Apr; 56(suppl_1):i32-i45. PubMed ID: 28013203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic lupus erythematosus and infections: clinical importance of conventional and upcoming biomarkers.
    Sciascia S; Ceberio L; Garcia-Fernandez C; Roccatello D; Karim Y; Cuadrado MJ
    Autoimmun Rev; 2012 Dec; 12(2):157-63. PubMed ID: 22498788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients.
    Higgs BW; Zhu W; Richman L; Fiorentino DF; Greenberg SA; Jallal B; Yao Y
    Int J Rheum Dis; 2012 Feb; 15(1):25-35. PubMed ID: 22324944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibodies, complement and type I interferon as biomarkers for personalized medicine in SLE.
    Biesen R; Rose T; Hoyer BF; Alexander T; Hiepe F
    Lupus; 2016 Jul; 25(8):823-9. PubMed ID: 27252258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers.
    Akhter E; Burlingame RW; Seaman AL; Magder L; Petri M
    Lupus; 2011 Oct; 20(12):1267-74. PubMed ID: 21813587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serial analysis of autoantibody responses to the collagen-like region of Clq, collagen type II, and double stranded DNA in patients with systemic lupus erythematosus.
    Sjoholm AG; Martensson U; Sturfelt G
    J Rheumatol; 1997 May; 24(5):871-8. PubMed ID: 9150075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares.
    Matrat A; Veysseyre-Balter C; Trolliet P; Villar E; Dijoud F; Bienvenu J; Fabien N
    Lupus; 2011 Jan; 20(1):28-34. PubMed ID: 20943718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-nucleosome antibodies as a disease activity marker in patients with systemic lupus erythematosus.
    Suleiman S; Kamaliah D; Nadeem A; Naing NN; Che Maraina CH
    Int J Rheum Dis; 2009 Jul; 12(2):100-6. PubMed ID: 20374326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.